IMC Chicago’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $40M | Buy |
1,422,800
+79,100
| +6% | +$2.11M | 0.01% | 580 |
|
|
2025
Q4 | $33.5M | Sell |
1,343,700
-434,500
| -24% | -$11M | 0.01% | 628 |
|
|
2025
Q3 | $45.3M | Buy |
1,778,200
+16,400
| +0.9% | +$405K | 0.02% | 492 |
|
|
2025
Q2 | $42.7M | Sell |
1,761,800
-54,000
| -3% | -$1.26M | 0.02% | 436 |
|
|
2025
Q1 | $46M | Sell |
1,815,800
-28,200
| -2% | -$738K | 0.03% | 343 |
|
|
2024
Q4 | $48.9M | Buy |
1,844,000
+32,900
| +2% | +$892K | 0.02% | 353 |
|
|
2024
Q3 | $52.4M | Sell |
1,811,100
-337,800
| -16% | -$9.85M | 0.03% | 298 |
|
|
2024
Q2 | $60.1M | Buy |
2,148,900
+353,800
| +20% | +$9.74M | 0.04% | 255 |
|
|
2024
Q1 | $49.8M | Buy |
1,795,100
+289,400
| +19% | +$8.03M | 0.03% | 252 |
|
|
2023
Q4 | $43.3M | Buy |
1,505,700
+752,200
| +100% | +$22.7M | 0.03% | 283 |
|
|
2023
Q3 | $25M | Buy |
753,500
+80,200
| +12% | +$2.84M | 0.02% | 323 |
|
|
2023
Q2 | $24.7M | Sell |
673,300
-40,600
| -6% | -$1.58M | 0.02% | 324 |
|
|
2023
Q1 | $29.1M | Sell |
713,900
-62,500
| -8% | -$2.7M | 0.03% | 256 |
|
|
2022
Q4 | $39.8M | Buy |
776,400
+56,000
| +8% | +$2.68M | 0.06% | 189 |
|
|
2022
Q3 | $31.5M | Sell |
720,400
-65,400
| -8% | -$3.18M | 0.04% | 205 |
|
|
2022
Q2 | $41.2M | Sell |
785,800
-302,600
| -28% | -$15.4M | 0.06% | 161 |
|
|
2022
Q1 | $56.3M | Sell |
1,088,400
-571,700
| -34% | -$29.7M | 0.06% | 148 |
|
|
2021
Q4 | $98M | Buy |
1,660,100
+255,800
| +18% | +$12.7M | 0.08% | 102 |
|
|
2021
Q3 | $60.4M | Buy |
1,404,300
+13,900
| +1% | +$616K | 0.06% | 156 |
|
|
2021
Q2 | $54.4M | Buy |
1,390,400
+278,900
| +25% | +$10.8M | 0.07% | 157 |
|
|
2021
Q1 | $40.3M | Buy |
+1,111,500
| New | +$39.5M | 0.06% | 174 |
|
|
2020
Q4 | – | Sell |
-497,066
| Closed | -$17.3M | – | 1091 |
|
|
2020
Q3 | $17.3M | Buy |
497,066
+335,277
| +207% | +$11.8M | 0.03% | 232 |
|
|
2020
Q2 | $5.02M | Sell |
161,789
-46,692
| -22% | -$1.59M | 0.01% | 374 |
|
|
2020
Q1 | $6.46M | Sell |
208,481
-82,950
| -28% | -$2.83M | 0.01% | 276 |
|
|
2019
Q4 | $10.8M | Sell |
291,431
-36,047
| -11% | -$1.28M | 0.03% | 206 |
|
|
2019
Q3 | $11.2M | Sell |
327,478
-6,956
| -2% | -$253K | 0.03% | 169 |
|
|
2019
Q2 | $13.7M | Buy |
334,434
+87,587
| +35% | +$3.48M | 0.04% | 133 |
|
|
2019
Q1 | $9.95M | Buy |
246,847
+16,443
| +7% | +$659K | 0.04% | 146 |
|
|
2018
Q4 | $9.54M | Buy |
+230,404
| New | +$9.56M | 0.03% | 124 |
|
Other funds holding PFE
VCM
VPM
IMC Chicago's PFE Position: Q3 2025 in Review
IMC Chicago sold out of Pfizer (PFE) in Q3 2025, closing a stake of 106,092 shares — an estimated $2.62M sold.
IMC Chicago first reported a position in PFE in Q3 2019 and held it in 7 quarters. The position peaked at $3.63M in Q1 2022. 2,811 funds tracked by Wall St. Rank hold PFE as of Q3 2025.
- IMC Chicago reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
- IMC Chicago sold 106,092 Pfizer shares in Q3 2025, an estimated $2.62M.
- IMC Chicago first reported a position in Pfizer in Q3 2019 and held it in 7 quarters.
- IMC Chicago's Pfizer position peaked at $3.63M in Q1 2022.
- 2,811 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.
Based on IMC Chicago's 13F filing for Q3 2025, filed 4 Nov 2025.